CM
MRSN

Caption Management’s Mersana Therapeutics MRSN Stock Holding History

Caption Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,480
Closed -$286K – 1428
2023
Q2 		$286K Buy
3,480
+1,400
+67% +$205K 0.01% 901
2023
Q1 		$214K Buy
2,080
+480
+30% +$67.4K ﹤0.01% 916
2022
Q4 		$234K Buy
+1,600
New +$270K ﹤0.01% 1043
2021
Q3 		– Sell
-3,500
Closed -$1.19M – 1683
2021
Q2 		$1.19M Sell
3,500
-8,416
-71% -$3.19M 0.02% 840
2021
Q1 		$4.82M Buy
+11,916
New +$5.78M 0.1% 254

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Caption Management's MRSN Position: Q4 2024 in Review

Caption Management sold out of Mersana Therapeutics (MRSN) in Q4 2024, closing a stake of 408 shares — an estimated $19.3K sold.

Caption Management first reported a position in MRSN in Q1 2021 and held it in 6 quarters. The position peaked at $3.98M in Q1 2021. 128 funds tracked by Wall St. Rank hold MRSN as of Q4 2024.

  • Caption Management reported no remaining Mersana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Caption Management sold 408 Mersana Therapeutics shares in Q4 2024, an estimated $19.3K.
  • Caption Management first reported a position in Mersana Therapeutics in Q1 2021 and held it in 6 quarters.
  • Caption Management's Mersana Therapeutics position peaked at $3.98M in Q1 2021.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2024.

Based on Caption Management's 13F filing for Q4 2024, filed 14 Feb 2025.